PepGen (PEPG) announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy until the company can review results from the 10 mg/kg cohort in the ongoing Phase 2 CONNECT1-EDO51 study. The first two cohorts of the CONNECT1 study are fully enrolled and data from the 10 mg/kg cohort are expected during the third quarter of 2025. No new safety issues related to PGN-EDO51 have been observed since the company’s last safety update as of January 23.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEPG:
- Promising Prospects for PepGen Inc.: Buy Rating Affirmed Amid Positive DM1 Treatment Developments
- Biotech Alert: Searches spiking for these stocks today
- PepGen Inc. Reports Positive Trial Results and Financials
- Sell Rating on PepGen Inc. Amid Clinical and Regulatory Challenges
- Apple to invest $500B in U.S., Domino’s reports downbeat Q4: Morning Buzz